Klotho Neurosciences, INC. (GRMLW) — SEC Filings

Overview

Klotho Neurosciences, INC. (GRMLW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S-1 filed on Dec 5, 2025: Klotho Neurosciences, Inc. (GRMLW) filed an S-1 on December 5, 2025, to register up to 35,000,000 shares of common stock for resale by existing selling stockholders. These shares include 34,883,722 shares issuable upon conversion of Series C Convertible Preferred Stock, which were sold in a private

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 8 bearish, 41 neutral, 1 mixed. The dominant filing sentiment for Klotho Neurosciences, INC. is neutral.

Filing Type Overview

Klotho Neurosciences, INC. (GRMLW) has filed 34 8-K, 3 S-1, 6 10-Q, 2 8-K/A, 1 DEF 14A, 2 10-K, 1 S-1/A, 1 SC 13G with the SEC between Mar 2024 to Dec 2025.

Filings by Year

2025 · 2024

Recent Filings (50)

• 8-K Filing — 8-K · Dec 8, 2025
• Klotho Neurosciences Files S-1 for $15M Preferred Stock Resale — S-1 · Dec 5, 2025 Risk: high
  Klotho Neurosciences, Inc. (GRMLW) filed an S-1 on December 5, 2025, to register up to 35,000,000 shares of common stock for resale by existing selling stockhol
• Klotho Neurosciences' Net Loss Widens to $9.2M Amid Soaring Expenses — 10-Q · Nov 13, 2025 Risk: high
  Klotho Neurosciences, Inc. (GRMLW) reported a net loss of $9,222,798 for the nine months ended September 30, 2025, a significant increase from the $4,083,109 ne
• Klotho Neurosciences Faces Delisting Concerns — 8-K · Sep 25, 2025 Risk: high
  Klotho Neurosciences, Inc. filed an 8-K on September 25, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard as of
• Klotho Neurosciences Files Q2 2025 10-Q — 10-Q · Aug 18, 2025 Risk: low
  Klotho Neurosciences, Inc. filed its quarterly report for the period ending June 30, 2025. The company, formerly known as ANEW Medical, Inc. and Redwoods Acquis
• Klotho Neurosciences Files 8-K: Material Agreement — 8-K · Aug 12, 2025 Risk: medium
  Klotho Neurosciences, Inc. entered into a Material Definitive Agreement on August 6, 2025. The company, formerly known as ANEW Medical, Inc. and Redwoods Acquis
• Klotho Neurosciences Files 8-K/A Amendment — 8-K/A · Jul 23, 2025 Risk: low
  Klotho Neurosciences, Inc. filed an amendment (8-K/A) on July 23, 2025, to a report originally dated August 26, 2024. This amendment pertains to the departure o
• Klotho Neurosciences Enters Material Definitive Agreement — 8-K · Jul 22, 2025 Risk: medium
  Klotho Neurosciences, Inc. announced on July 16, 2025, that it entered into a Material Definitive Agreement. The company, formerly known as ANEW Medical, Inc. a
• Klotho Neurosciences Faces Delisting Concerns — 8-K · Jul 18, 2025 Risk: high
  Klotho Neurosciences, Inc. filed an 8-K on July 18, 2025, reporting a notice of delisting or failure to satisfy continued listing rules. The company, formerly k
• Klotho Neurosciences Files 8-K — 8-K · Jul 10, 2025 Risk: low
  Klotho Neurosciences, Inc. filed an 8-K on July 10, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly know
• Klotho Neurosciences Files 8-K — 8-K · Jun 30, 2025 Risk: low
  Klotho Neurosciences, Inc. filed an 8-K on June 30, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly know
• Klotho Neurosciences Files 8-K — 8-K · Jun 16, 2025 Risk: low
  Klotho Neurosciences, Inc. filed an 8-K on June 16, 2025, reporting on other events and financial statements. The company, formerly known as ANEW Medical, Inc.
• Klotho Neurosciences Reports Material Agreement & Equity Sales — 8-K · Jun 13, 2025 Risk: medium
  Klotho Neurosciences, Inc. filed an 8-K on June 13, 2025, reporting on events that occurred on June 9, 2025. The filing indicates an entry into a material defin
• Klotho Neurosciences Files 8-K on Agreements — 8-K · Jun 11, 2025 Risk: medium
  Klotho Neurosciences, Inc. filed an 8-K on June 11, 2025, reporting on an entry into a material definitive agreement and unregistered sales of equity securities
• Klotho Neurosciences Enters Material Definitive Agreement — 8-K · Jun 10, 2025 Risk: medium
  Klotho Neurosciences, Inc. announced on June 5, 2025, that it entered into a Material Definitive Agreement. The company, formerly known as Redwoods Acquisition
• Klotho Neurosciences Files 8-K on Shareholder Votes & Financials — 8-K · Jun 2, 2025 Risk: low
  Klotho Neurosciences, Inc. filed an 8-K on May 28, 2025, reporting on the submission of matters to a vote of security holders and financial statements. The comp
• Klotho Neurosciences Files Q1 2025 10-Q — 10-Q · May 15, 2025 Risk: low
  Klotho Neurosciences, Inc. filed its quarterly report for the period ended March 31, 2025. The company, formerly known as ANEW Medical, Inc. and Redwoods Acquis
• Klotho Neurosciences Files Proxy Statement for May 28 Meeting — DEF 14A · May 5, 2025 Risk: low
  Klotho Neurosciences, Inc. filed its definitive proxy statement on May 5, 2025, for its annual meeting on May 28, 2025. The company, formerly known as Redwoods
• Klotho Neurosciences Faces Nasdaq Delisting Warning — 8-K · Apr 21, 2025 Risk: high
  Klotho Neurosciences, Inc. has received a notice from the Nasdaq Stock Market indicating that the company is not in compliance with the minimum bid price requir
• Klotho Neurosciences, Inc. Files 8-K, Details Name Changes — 8-K · Apr 4, 2025 Risk: low
  Klotho Neurosciences, Inc. filed an 8-K on April 4, 2025, reporting an event on March 31, 2025. The filing indicates the company's former names were ANEW Medica
• Klotho Neurosciences Files 8-K for Material Agreement — 8-K · Apr 1, 2025 Risk: medium
  Klotho Neurosciences, Inc. filed an 8-K on April 1, 2025, reporting a material definitive agreement entered into on March 26, 2025. The filing also includes fin
• 10-K Filing — 10-K · Mar 31, 2025
• Klotho Neurosciences Faces Delisting Notice — 8-K · Feb 24, 2025 Risk: high
  Klotho Neurosciences, Inc. filed an 8-K on February 24, 2025, reporting a notice of delisting or failure to meet continued listing standards as of February 14,
• Klotho Neurosciences Files S-1 for Public Offering — S-1 · Jan 30, 2025 Risk: medium
  Klotho Neurosciences, Inc. filed an S-1 registration statement on January 30, 2025, to register securities for public offering. The company, formerly known as A
• Klotho Neurosciences Enters Material Agreement, Reports Financial Obligations — 8-K · Jan 24, 2025 Risk: medium
  Klotho Neurosciences, Inc. announced on January 23, 2025, that it entered into a material definitive agreement. The company also reported the creation of a dire
• Klotho Neurosciences Reports Definitive Agreement & Equity Sales — 8-K · Dec 10, 2024 Risk: medium
  Klotho Neurosciences, Inc. entered into a material definitive agreement on December 4, 2024, related to the creation of a direct financial obligation. The compa
• Klotho Neurosciences Reports Director/Officer Changes & Financials — 8-K · Nov 25, 2024 Risk: medium
  Klotho Neurosciences, Inc. filed an 8-K on November 25, 2024, reporting events as of November 19, 2024. The filing pertains to the departure of directors or cer
• Klotho Neurosciences Files Q3 2024 10-Q — 10-Q · Nov 19, 2024 Risk: medium
  Klotho Neurosciences, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2024. The company, formerly known as ANEW Medical, Inc. an
• Klotho Neurosciences Terminates Material Agreement — 8-K · Nov 13, 2024 Risk: medium
  Klotho Neurosciences, Inc. reported the termination of a material definitive agreement on November 8, 2024. The company, formerly known as ANEW Medical, Inc. an
• Klotho Neurosciences Files 8-K on Officer/Director Changes — 8-K · Oct 31, 2024 Risk: medium
  Klotho Neurosciences, Inc. filed an 8-K on October 31, 2024, reporting events that occurred on October 24, 2024. The filing pertains to the departure of directo
• Klotho Neurosciences Faces Delisting Concerns — 8-K · Oct 21, 2024 Risk: high
  Klotho Neurosciences, Inc. filed an 8-K on October 21, 2024, reporting a notice of delisting or failure to satisfy continued listing rules as of October 14, 202
• Klotho Neurosciences Files 8-K — 8-K · Oct 2, 2024 Risk: low
  Klotho Neurosciences, Inc. filed an 8-K on October 2, 2024, reporting an event on September 24, 2024. The company, formerly known as ANEW Medical, Inc. and Redw
• ANEW Medical Files S-1/A for IPO — S-1/A · Sep 13, 2024 Risk: medium
  ANEW Medical, Inc. filed an S-1/A amendment on September 13, 2024, for its initial public offering. The company, formerly known as Redwoods Acquisition Corp. un
• ANEW Medical Files S-1 Registration — S-1 · Sep 5, 2024 Risk: medium
  ANEW Medical, Inc. has filed an S-1 registration statement with the SEC. The company, formerly known as Redwoods Acquisition Corp. until January 27, 2022, is in
• ANEW Medical Announces Board and Executive Changes — 8-K · Aug 30, 2024 Risk: medium
  On August 25, 2024, ANEW Medical, Inc. filed an 8-K report detailing changes in its board of directors and executive officers. The filing includes information o
• ANEW Medical Faces Delisting Concerns — 8-K · Aug 22, 2024 Risk: high
  ANEW Medical, Inc. (formerly Redwoods Acquisition Corp.) filed an 8-K on August 22, 2024, reporting a notice of delisting or failure to satisfy continued listin
• ANEW Medical Files Q2 2024 10-Q Report — 10-Q · Aug 19, 2024 Risk: low
  ANEW Medical, Inc. filed its quarterly report on Form 10-Q for the period ended June 30, 2024. The company, formerly known as Redwoods Acquisition Corp. until J
• ANEW Medical Appoints New CMO, Director — 8-K · Aug 5, 2024 Risk: medium
  On July 30, 2024, ANEW Medical, Inc. announced the appointment of Dr. David L. Smith as Chief Medical Officer and the election of Ms. Jennifer L. Smith to its B
• ANEW Medical Completes Major Transaction, Changes Control — 8-K · Jun 27, 2024 Risk: high
  On June 21, 2024, ANEW Medical, Inc. (formerly Redwoods Acquisition Corp.) completed a significant transaction, entering into a material definitive agreement an
• SC 13G Filing — SC 13G · Jun 27, 2024
• Redwoods Acquisition Corp. Files 8-K — 8-K · Jun 20, 2024 Risk: low
  Redwoods Acquisition Corp. filed an 8-K on June 20, 2024, reporting on other events and financial statements. The company, incorporated in Delaware, is involved
• Redwoods Acquisition Corp. Files 8-K/A Amendment — 8-K/A · Jun 14, 2024 Risk: medium
  Redwoods Acquisition Corp. filed an amendment (8-K/A) on June 14, 2024, related to events on June 13, 2024. The filing concerns entry into a material definitive
• Redwoods Acquisition Corp. Files 10-Q for Q1 2024 — 10-Q · May 23, 2024 Risk: low
  Redwoods Acquisition Corp. filed its 10-Q for the quarterly period ended March 31, 2024. The company, incorporated in Delaware, operates in the Biological Produ
• Redwoods Acquisition Corp. Files Material Definitive Agreement — 8-K · May 10, 2024 Risk: medium
  On May 9, 2024, Redwoods Acquisition Corp. filed an 8-K report detailing a material definitive agreement. The company, incorporated in Delaware with its princip
• Redwoods Acquisition Corp. Files 8-K on Shareholder Votes — 8-K · Apr 18, 2024 Risk: low
  Redwoods Acquisition Corp. filed an 8-K on April 18, 2024, reporting on matters submitted to a vote of security holders and a Regulation FD disclosure. The fili
• Redwoods Acquisition Corp. Files 2023 Annual Report on Form 10-K — 10-K · Apr 17, 2024 Risk: low
  Redwoods Acquisition Corp. (GRMLW) filed a Annual Report (10-K) with the SEC on April 17, 2024. Redwoods Acquisition Corp. filed its annual report for the fisca
• Redwoods Acquisition Corp. Files 8-K — 8-K · Apr 12, 2024 Risk: low
  Redwoods Acquisition Corp. filed an 8-K on April 12, 2024, reporting an event on April 8, 2024. The filing pertains to their status as a SPAC (Special Purpose A
• Redwoods Acquisition Corp. Files 8-K on Corporate Structure Changes — 8-K · Apr 5, 2024 Risk: low
  Redwoods Acquisition Corp. filed an 8-K on April 5, 2024, reporting an event on April 1, 2024. The filing indicates changes related to its units, common stock,
• Redwoods Acquisition Corp. Files 8-K — 8-K · Mar 22, 2024 Risk: low
  Redwoods Acquisition Corp. filed an 8-K on March 22, 2024, to report other events. The company, incorporated in Delaware, is involved in the biological products
• Redwoods Acquisition Corp. Files 8-K on Corporate Structure — 8-K · Mar 11, 2024 Risk: low
  Redwoods Acquisition Corp. filed an 8-K on March 11, 2024, reporting an event that occurred on March 8, 2024. The filing pertains to the company's structure, in

Risk Profile

Risk Assessment: Of GRMLW's 47 recent filings, 9 were flagged as high-risk, 19 as medium-risk, and 19 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Klotho Neurosciences, INC.'s most recent 10-Q filing (Nov 13, 2025):

• Revenue: N/A
• Net Income: -$9.22M
• EPS: -$0.23
• Debt-to-Equity: 0.01
• Cash Position: $7.35M
• Operating Margin: N/A
• Total Assets: $10.07M
• Total Debt: $0.15M

Key Executives

• Joseph A. Sinkule
• Paul Goodman, Esq.
• Dr. David L. Smith
• Ms. Jennifer L. Smith

Industry Context

Klotho Neurosciences operates in the biotechnology and pharmaceutical sector, focusing on neuroscience. This industry is characterized by high research and development costs, long development cycles, and significant regulatory hurdles. Companies in this space often rely on private placements and public offerings to fund their operations and clinical trials.

Top Tags

filing (8) · material-agreement (7) · company-name-change (7) · delisting (5) · 10-Q (5) · quarterly-report (5) · corporate-actions (5) · equity-sale (5) · listing-standards (4) · 8-K (4)

Key Numbers

• Shares of Common Stock offered by Selling Stockholders: 35,000,000 — Represents the maximum number of shares that may be resold, including 34,883,722 from Series C conversion and 1,000,000 already held.
• Shares of Common Stock Outstanding Prior to Offering: 72,536,722 — Provides context for the potential dilution from the resale offering.
• Aggregate Purchase Price of Series C Preferred Stock: $15,000,000 — The amount raised by Klotho Neurosciences from the private placement, the shares from which are now being registered for resale.
• Conversion Price per share for Series C Preferred Stock: $0.44 — The effective price at which Series C Preferred Stock converts into common stock.
• Average Common Stock Price on Dec 2, 2025: $0.43 — The market price used for registration fee calculation and a recent trading indicator.
• Maximum Percentage Ownership for Conversion: 9.99% — A restriction on conversion of Series C Preferred Stock to prevent any single investor from owning too much common stock.
• Net Loss: $9.22M — Increased from $4.08M in 2024 for the nine months ended September 30, 2025
• Accumulated Deficit: $19.79M — As of September 30, 2025, indicating significant historical losses
• Cash and Cash Equivalents: $7.35M — Increased from $63,741 at December 31, 2024, due to financing activities
• Net Cash from Financing: $11.89M — Provided for the nine months ended September 30, 2025, crucial for liquidity
• Interest Expense: $3.49M — Significantly increased from $60,020 in 2024 for the nine months ended September 30, 2025
• Common Stock Shares Outstanding: 70,334,792 — As of September 30, 2025, up from 27,080,915 at December 31, 2024
• Total Operating Expenses: $5.33M — Increased from $3.69M in 2024 for the nine months ended September 30, 2025
• Research and Development: $509,845 — New expense for the nine months ended September 30, 2025, indicating investment in pipeline
• Commission File Number: 001-41340 — Identifies the company's SEC filing history.

Related Companies

KLTO · KLTOW · RWOD

Frequently Asked Questions